The new site adds research capacity and reportedly strengthens the company’s U.S. footprint beyond its existing facility and manufacturing operations in New Jersey.
The project includes digital transformation initiatives and process-innovation technologies to more than double production capacity at the company’s Ansan site.
The new location in Research Triangle Park strengthens AES’s support for the expanding life sciences and manufacturing industries in the Southeastern United States.
The partnership aims to strengthen financial flexibility and accelerate international growth for the bioconjugate-focused contract research, development, and manufacturing organization...
The company’s proprietary manufacturing enhancers reportedly boost adeno-associated virus production efficiency, while maintaining product integrity across scales.
The newly formed company from the businesses of Mallinckrodt and Endo, which merged in July 2025, will focus on branded therapeutics for rare and underserved conditions.
The collaboration combines mRNA sequence optimization with end-to-end GMP manufacturing to support streamlined development and clinical-scale production.
The completed deal expands Sandoz’s biosimilar manufacturing footprint while enabling Evotec to transition toward a more asset-light, technology-driven business model.
The $22.2 million agreement aims to advance domestic production of monoclonal antibodies to protect against filoviruses such as Ebola and Sudan viruses.
The collaboration aims to strengthen the U.S. advanced pharmaceutical manufacturing workforce through a new industry-led education and training network.
The agreement aims to establish cell-based influenza vaccine manufacturing to strengthen Saudi Arabia’s pandemic preparedness, according to the companies.
The CDMO is channeling new capital toward ongoing efforts to shift operations to biologics and aseptic drug production at its core sites in Cincinnati and Toronto.
The collaboration will combine U.S. and South Korean CDMO networks to deliver integrated ADC manufacturing services and strengthen supply chain resilience.
New funding reportedly supports Recipharm’s development of a digital manufacturing platform to advance continuous vaccine production and improve global access.
The company will partner with Saudi Arabia’s government and a new high-tech industrial region to develop research and manufacturing capacity in the Middle East.
The CDMO’s refreshed identity aligns with its “Championing the Missions that Matter” messaging and reflects its continued evolution under the ownership of Novo Holdings.